Intelligence · Clinical Development
Pipeline search results
Programs matching “pembrolizumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 75 pipeline programs matching "pembrolizumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Pembrolizumab
Inhibrx Biosciences
Triple Negative Breast Cancer
1 trial -
Pembrolizumab
Bicara Therapeutics
Head and Neck Squamous Cell Carcinoma
1 trial -
Pembrolizumab
ALX ONCOLOGY HOLDINGS INC
Ovarian Cancer
1 trial -
Pembrolizumab
Karyopharm Therapeutics Inc
Advanced Urothelial Carcinoma
1 trial -
Pembrolizumab
IO Biotech
Head and Neck Squamous Cell Carcinoma
1 trial -
Pembrolizumab (+) Berahyaluronidase alfa
Merck KGaA, Darmstadt, Germany
Squamous Cell Carcinoma
1 trial -
Pembrolizumab (200mg IV for 30 minutes
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Pembrolizumab (KEYTRUDA®) and PDS0101
PDS Biotechnology Corp
Metastatic Head and Neck Cancer
1 trial -
Pembrolizumab 200 mg
Merck KGaA, Darmstadt, Germany
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Pembrolizumab 200 mg
Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
1 trial -
Pembrolizumab 200 mg IV infusion
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stage IIIB(N2) Non-small Cell Lung Cancer
1 trial -
Pembrolizumab Injection
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Pembrolizumab plus denosumab
Zealand Pharma A/S
Renal Cell Carcinoma, Clear Cell
1 trial -
Pembrolizumab/Vibostolimab coformulation
Merck KGaA, Darmstadt, Germany
Metastatic Non Small Cell Lung Cancer
1 trial -
Phase 1b: APG-115+pembrolizumab
Ascentage Pharma Group
Unresectable or Metastatic Melanoma or Advanced Solid Tumors
1 trial -
ZZ-IT-ICI-HCC 1line-023
Second Affiliated Hospital of Soochow University
Liver Cancer
1 trial -
pembrolizumab
The University of Hong Kong
T-Cell Lymphoma
1 trial -
pembrolizumab
The First People's Hospital of Lianyungang
Advanced Non-squamous Non-small-cell Lung Cancer
1 trial -
pembrolizumab
Hospital Authority, Hong Kong
Locally Recurrent Cancer
1 trial -
pepinemab + pembrolizumab
VACCINEX, INC.
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
1 trial -
Comparison between ABP 234 and Keytruda® (Pembrolizumab)
Amgen
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
1 trial -
INSIGHT
The George Institute
Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)
1 trial -
Pembrolizumab
Takeda
Carcinoma, Non-Small-Cell Lung
1 trial -
Pembrolizumab
United Therapeutics Europe Ltd
Thoracic Tumours
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.